Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Real World Evidence

BBCR Company News

Inventor of the PCR, Kary Mullis, Dies

August 15th, 2019 | Real World Evidence

Longer Stretch To The Finish Line for CNS Diseases

August 7th, 2019 | Real World Evidence

Cost vs. Value: Can We Have Both?

August 1st, 2019 | Real World Evidence

Could Seamless Adaptive Designs Advance Rare Disease Clinical Trial Design?

July 24th, 2019 | Real World Evidence

Gene Therapy for Rare Disorders Europe 2019 – October 15th – 17th, London

July 15th, 2019 | Real World Evidence

BBCR is Hiring! Boston Biotech Clinical Research is looking for a Full Time Associate Clinical Scientist to join our team!

June 21st, 2019 | Real World Evidence

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Real World Evidence

A success story by BBCR Consulting: Candida Fratazzi MD was CMO at Ichorion Therapeutics in 2018

December 17th, 2018 | Real World Evidence

Welcome to BBCR’s New Website!

December 7th, 2018 | Real World Evidence
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • BBCR partners with clients to identify, develop, and advance a product’s unique strengths from early concept through to market. Our consultancy is grounded in deep expertise across cell, biologic, and gene therapies, with a particular focus on rare disease.
  • BBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work collaboratively with a product developer on the best plan to market. To learn more, visit bbcrconsulting.com.
  • Drug repurposing accelerates the path from discovery to the clinic, offering particular promise for rare, neglected, oncologic, and neurodegenerative diseases. Learn how we can help at bbcrconsulting.com
  • Is Your Drug Development Strategy Built for Tomorrow’s Success?
  • BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.

RSS Nasdaq Globe Newswire

  • Liberation Bioindustries Announces New Roles for Founders January 15, 2026
  • Rare Cell Isolation Market Forecast Report 2025-2033 - Opportunities in Biotechnology Advancements and Precision Medicine January 15, 2026
  • Fetal Bovine Serum Market Size, Share & Trends Analysis Report 2025-2033 January 15, 2026
  • Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration January 15, 2026
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs